N@N

Michael Ulz Maintained (YMAB) at Sell with Increased Target to $7 on, May 10th, 2023

Michael Ulz of Morgan Stanley, Maintained "Y-mAbs Therapeutics, Inc." (YMAB) at Sell with Increased Target from $4 to $7 on, May 10th, 2023.

Michael has made no other calls on YMAB in the last 4 months.

There are 5 other peers that have a rating on YMAB. Out of the 5 peers that are also analyzing YMAB, 2 agree with Michael's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Etzer Darout of "Guggenheim" Downgraded from Strong Buy to Hold on, Monday, April 3rd, 2023
• Alec Stranahan of "B of A Securities" Maintained at Hold and Held Target at $6 on, Saturday, April 1st, 2023

These are the ratings of the 3 analyists that currently disagree with Michael

---

• William Plovanic of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $21 on, Tuesday, May 9th, 2023
• Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $11 on, Tuesday, April 4th, 2023
• William Maughan of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $18 on, Friday, March 31st, 2023

Contributing Sources

---